Receive The Newest Study Notifications

Phase 2-3 AAVance study in MPS IIIA fully on track with seven children already safely treated with LYS-SAF302 Completion of robust two-year natural history study in MPS IIIA to serve as control arm for Phase 2-3 Launch of PROVide, parallel study using home-based smart...

Results of a phase II clinical trial released today in STEM CELLS Translational Medicine (SCTM) indicate that a limbal stem cell (LSC) transplantation is superior to a tissue graft in treating limbal stem cell deficiency syndrome (LSCD). DURHAM, N.C., September 5,...

OWLS (Organizational Wellness and Learning Systems), a science-based consulting and training service in the area of Integral Organizational Wellness™, today announced new findings of a clinical trial that evaluated the efficacy of evidence-based online technology that...

Dual mechanisms, rapid absorption and long half-life support therapeutic potential of AXS-07 in migraine AXS-07 MOMENTUM Phase 3 trial ongoing in migraine patients with history of inadequate response to prior acute treatments NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE)...

Preliminary Phase 1 Data Expected by the End of 2019 Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces that the first patient received investigational therapy in the...

Enrollment Completed for ORION-1 Phase 2b Glaucoma Trial with Data Expected in Q4 2019 Enrollment Near Completion for MIRA-1 Phase 2b Reversal of Mydriasis Trial with Data Expected in Q4 2019 Company to Present at H.C. Wainwright 21st Annual Global Investment...

A prospective study comparison of the mobile medical game, OdySight, with standard clinical eye tests Study concludes that OdySight would be a good alternative for remote monitoring of vision between clinic visits, and could potentially assist in follow-up planning...

CoNextions Medical, a developer of novel soft tissue repair devices, announced today that it has completed enrollment in a key clinical trial for its pioneering tendon-to-tendon repair device, CoNextions TR. Pending successful results of the trial, the company plans...

People allergic to peanuts may have a new way to protect themselves from severe allergic reactions to accidental peanut exposure. It's called sublingual immunotherapy - or SLIT - and it involves putting a miniscule amount of liquefied peanut protein under the tongue,...

PARP7 is a Novel Tumor Dependency, Enabling Cancer Cells to Evade the Immune System First Ever Clinical Evaluation of a monoPARP Inhibitor Ribon Therapeutics, a biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated...

-- MARIO-3 Phase 2 Study to Evaluate Triple Combination Therapy with IPI-549 in the Frontline Setting in Triple Negative Breast Cancer and Renal Cell Cancer -- -- Phase 1/1b Study with Arcus Biosciences to Evaluate Triple Combination Therapy with IPI-549 in Advanced...

Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, today announced results from the Company's first-in-patient Phase 2...

Data Demonstrate Safety and Tolerability of Microbiome Metabolic Therapy (MMT™) Candidate KB195 and Potential for Effect on Nitrogen Metabolism, a Biomarker of Ammonia Production LEXINGTON, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (KLDO), a...

– Confirmed objective responses achieved in five of 13 evaluable patients – – Primary endpoint met prior to completion of enrollment with four patients experiencing progression-free survival greater than 6 months – – Proof-of-concept trial sponsored by Samsung Medical...

Regulatory News: Celyad (Paris:CYAD) (Brussels:CYAD) (NASDAQ:CYAD) (Euronext Brussels and Paris, and Nasdaq:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced the successful administration of...

Leuven, Belgium, 4 September 2019 - 7.30 AM CET- Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing innovative treatments to preserve vision in patients with diabetic eye disease, announces the completion of enrollment of patients in a Phase...

Mark Terry of Biospace writes:  Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories. Emerald Health Pharmaceuticals completed its first-in-human Phase I clinical trial of EHP-101 in multiple...

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) announced today the dosing of the first patient in the Phase 3 clinical study PRINCE (APL2-308), evaluating the efficacy and safety of APL-2 for treatment-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH). PRINCE...

Odiparcil development advances with recruitment of first patients in a new biomarker study in MPS VI children and adults Study conducted in the United-States aims to consolidate leucocyte GAG and skin GAG content measurement as disease biomarkers in MPS VI children...

New peer-reviewed, published research finds that daily use of the dietary ingredient BioCell Collagen® can visibly reduce facial lines and crow's feet wrinkles and boost skin elasticity IRVINE, California, Sept. 3, 2019 /PRNewswire/ -- In one of the most substantial...